Lena Medical Showcases Multiple Innovative ENT Devices at National Otorhinolaryngology Congress and Files IPO Prospectus

Recently, hosted by the Chinese Medical Association and its Branch of Otorhinolaryngology–Head and Neck Surgery,The 18th National Academic Conference of Otorhinolaryngology-Head and Neck Surgery of the Chinese Medical Associationconcluded at the Suzhou Jinji Lake Convention Center.

As the most influential, academically prestigious, and largest academic conference in China’s field of otolaryngology–head and neck surgery, the congress facilitated academic exchanges centered on this specialty.

At this academic conference showcasing the latest research findings and cutting-edge issues in the field of otorhinolaryngology–head and neck surgery in China, and promoting the comprehensive development of the discipline,“ENT” Dedicated to Local InnovationLeno Medical, a medical device company in the field, also brought and showcased several of its star products.

In recent years,The incidence of diseases related to otorhinolaryngology and head and neck surgery in China is showing a year-on-year upward trend.

According to the "Chinese Guidelines for the Diagnosis and Treatment of Chronic Rhinosinusitis (2018)," there are over 100 million patients with chronic rhinosinusitis in China, including 7 million severe cases urgently requiring surgical intervention.There are over 30 million patients with moderate conditions requiring medical intervention. However, even in 2021, the actual number of patients who underwent surgical intervention was less than one-third, with an estimated 2 million procedures performed in otolaryngology and head and neck surgery.Five years earlier, the surgical volume was as low as 500,000 cases.

Furthermore,Diseases that severely impact public health, such as obstructive sleep apnea (OSA), also exhibit high prevalence. The current number of individuals with OSA has reached 176 million, including 66 million patients with moderate-to-severe OSA.Untreated OSA is prone to causing cardiovascular complications and even sudden death.

Both chronic rhinosinusitis and obstructive sleep apnea (OSA) impose a substantial economic burden on patients and society.

However, resolving the aforementioned issues is not as easy as one might imagine.

Experts from participating hospitals; second from the left is Professor Liu Shixi, Director of the Department of Otolaryngology–Head and Neck Surgery at West China Hospital of Sichuan University.

Professor Liu Shixi, Director of the Department of Otolaryngology-Head and Neck Surgery at West China Hospital of Sichuan University, pointed out, “With the improvement of living standards among Chinese people and the acceleration of urban life pace, there is a particularly high volume of patients seeking consultation and treatment in otolaryngology–head and neck surgery departments. From the perspective of physicians and clinical departments,”We look forward to seeing more domestic innovative enterprises, represented by Lainuo Medical Technology, proactively and foresightedly align with clinical medical needs, helping physicians enhance surgical and therapeutic techniques, and delivering safer, more efficient, and convenient healthcare solutions for patients.”

It is necessary to “actively and proactively align with clinical medical needs, helping physicians enhance surgical and therapeutic techniques,” while also “providing patients with safer, more efficient, and more convenient healthcare solutions.” These two objectives are sometimes fraught with contradictions and are not as easy to achieve as one might imagine. Tackling this challenging task requires companies to be prepared for long-term investment.

Established in 2015, “having witnessed and personally experienced the exponential growth of the otorhinolaryngology and head and neck surgery market over the past five years”Cui Teng, Founder and Chairman of Lainuo Medical, stated, “Lainuo Medical will more resolutely focus on the emerging market of otorhinolaryngology–head and neck surgery,” and “continuously leverage innovative technologies to help doctors and medical institutions enhance their treatment standards, thereby making a modest contribution to the quality of life and health well-being of the Chinese people.”

At the Academic Conference of Otorhinolaryngology-Head and Neck Surgery of the Chinese Medical Association,Leno Medical brought and showcased a range of star products, including sinus dilation balloons, Eustachian tube dilation balloons, snoring stents, the Meichuang low-temperature plasma surgical system, and Sico ENT surgical instruments.

In fact, since its establishment in 2015,Leno MedicalWe have been dedicated to the field of otolaryngology, engaging in the research and development, manufacturing, and sales of single-use interventional medical devices, while providing patients with comprehensive diagnostic and therapeutic services.Its core products include sinus balloon catheters, Eustachian tube balloons, disposable nasopharyngeal airways, nasolacrimal duct balloons, and drug-eluting sinus stents.

Left: Cui Teng, Founder and Chairman of Lenor Medical

Regarding how companies should strategize their layout for innovative “ENT” medical devices, Cui Teng pointed out in an interview that, as a domestic innovator,Laino Medical“Not only by independently developing technologies and licensing the introduction of foreign product pipelines, but also by actively planning mergers and acquisitions of outstanding domestic and international enterprises, to further solidify the foundation of Lainuo Medical as an innovative technology platform company in the field of ENT and head and neck surgery in China.”

The medical device products showcased by Lainuo Medical at this conference actually align with its strategy for innovative medical device deployment in the “ENT” (Ear, Nose, and Throat) field. For instance, the Meichuang Low-Temperature Plasma Surgical System is a flagship product of Chengdu Meichuang, which Lainuo Medical acquired in December 2019. Meanwhile, the Sco surgical instruments are part of the product portfolio from Lainuo Medical’s latest acquisition, completed in October of this year.

At the meeting,Dr. Qian Yongwei, Co-founder, Director, and COO of Leno Medical, also introduced the company’s proprietary biodegradable sinus stent. The product is currently in the clinical development stage, and Leno Medical is poised to become the first manufacturer in China to launch it.This stent is extremely easy to operate, suitable for the treatment of patients with mild-to-moderate chronic sinusitis, and has a degradation cycle of less than 90 days.

“Addressing unmet clinical needs and continuously expanding the product pipeline through a tripartite business model encompassing independent R&D, licensed in-licensing, and strategic investments and M&A.”, this strategy was perfectly elucidated at the meeting.

It is important to highlight that,Lainuo Medical acquired Hangzhou Tonglu Sike Medical Instrument Co., Ltd. this year,The company is dedicated to the independent research, development, and manufacturing of surgical instruments for otolaryngology–head and neck surgery, with a product portfolio comprising nearly 1,000 varieties.Through this acquisition, in addition to gaining Scoco Medical’s extensive portfolio of medical devices, Leno Medical has further enriched its integrated solutions for otolaryngology and head and neck surgery.

Laino Medical’s independent R&D and innovation in the field of otolaryngology have also provided it with greater opportunities to engage with the most advanced medical technologies and equipment in this sector. In terms of R&D, comparisons with products from international peers have made them aware ofThe Importance of Introducing Advanced Medical Equipment and Devices—Compared to the lengthy R&D cycle, it enables domestic patients to gain access to high-quality medical devices more rapidly when similar products are lacking in the market.

Based on this, Lenor Medical is also actively introducing outstanding foreign medical devices and technologies through licensing. Currently, it has introduced products such as the Mega treatment table from South Korea, endoscopy systems, and navigation equipment. AndIts inherent ability to reach 30,000 ENT and head and neck surgery professionals, coupled with its specialized channel capabilities, enables it to build a professional commercial conversion platform that helps lesser-known but high-quality medical devices gain external adoption and attention.Leveraging its professional commercialization platform, Laino Medical actively introduces advanced foreign medical devices and technologies, continuously bringing new products and therapies to the domestic market and benefiting over 100 million patients with otolaryngology and head and neck surgical conditions.

Currently, Lainuo Medical holds a leading position in the domestic ENT diagnosis and treatment market.Serving thousands of medical institutions specializing in otorhinolaryngology and head and neck surgery, both domestically and internationally.Perhaps, as Professor Liu Shixi hopes, Lenor Medical will further focus on the “ENT” field,“To provide ENT and head and neck surgeons with a safer, more effective, and more convenient surgical experience, while offering patients a more economical, safer, and more effective treatment option.”